LGND Ligand Pharmaceuticals Incorporated

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND

Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ:LGND) from November 9, 2015 through November 14, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Ligand investors under the federal securities laws.

To join the Ligand class action, go to http://www.rosenlegal.com/cases-996.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Ligand overstated the value of certain Deferred Tax Assets by approximately $27.5 million or 13%; (2) Ligand’s outstanding convertible senior unsecured notes due 2019 should have been classified as short-term debt rather than long-term debt as of December 31, 2015; (3) Ligand did not maintain effective controls over the accuracy and presentation of the accounting for income taxes related to complex transactions; (4) in turn, Ligand lacked effective internal control over financial reporting; and (5) as a result, Defendants’ statements about Ligand’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-996.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

EN
18/11/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ligand Pharmaceuticals Incorporated

 PRESS RELEASE

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share1 of $8.00-$9.00 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2025, and provided an operating forecast and business update. Ligand man...

 PRESS RELEASE

Ligand to Report Fourth Quarter and Full Year 2025 Financial Results o...

Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, February 26, 2026  Time: 8:30 AM Eastern Time  Conference Call:(800) 715-9871 (U.S. & Canada)(646) 3...

 PRESS RELEASE

Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Scien...

Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which will be held virtually, on February 25, 2026 at 10:00 a.m. Eastern Time. Ligand management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interes...

Ligand Pharmaceuticals Inc: 1 director

A director at Ligand Pharmaceuticals Inc sold 1,804 shares at 188.310USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

 PRESS RELEASE

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted share of $8.00 to $9.002Increases 5-year royalty receipt outlook driven by Filspari, Ohtuvayre, and Zelsuvmi; expects to meet or exceed 23% compound annual growth rate$1 billion in deployable capital expected to drive long-term royalty revenue growth JUPITER, Fla., Dec. 09, 2025 (GLOBE ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch